Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EVFMNASDAQ:IMVNASDAQ:ONCTNASDAQ:OPTNNASDAQ:PRQR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVFMEvofem Biosciences$0.01$0.02$0.01▼$3.75$690K-1.12714,855 shs740,620 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsONCTOncternal Therapeutics$8.61-1.8%$8.85$5.57▼$13.14$23.57M1.266,852 shs1,600 shsOPTNOptiNose$0.93-4.1%$1.48$0.86▼$2.10$109.01M-0.24474,725 shs571,324 shsPRQRProQR Therapeutics$2.01-0.5%$2.14$1.11▼$3.29$164.34M0.21151,161 shs36,411 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVFMEvofem Biosciences+16.04%+9.56%-22.56%-50.00%-99.43%IMVIMV0.00%0.00%0.00%0.00%+1.54%ONCTOncternal Therapeutics-1.77%-1.15%+4.87%-4.01%+32.46%OPTNOptiNose-4.38%-9.28%-38.31%-36.62%-47.72%PRQRProQR Therapeutics-0.50%+5.79%-15.90%-3.83%-9.46%One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal Therapeutics2.4305 of 5 stars3.33.00.00.01.91.71.3OPTNOptiNose3.1491 of 5 stars3.53.00.04.20.02.50.6PRQRProQR Therapeutics1.4735 of 5 stars3.54.00.00.01.90.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVFMEvofem Biosciences2.00HoldN/AN/AIMVIMV2.00HoldN/AN/AONCTOncternal Therapeutics2.67Moderate Buy$31.33263.92% UpsideOPTNOptiNose3.00Buy$4.00332.29% UpsidePRQRProQR Therapeutics3.00Buy$3.6079.10% UpsideCurrent Analyst RatingsLatest OPTN, PRQR, EVFM, IMV, and ONCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.004/15/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.003/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.001/29/2024ONCTOncternal TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVFMEvofem Biosciences$18.22M0.04$1.49 per share0.01($2.64) per share-0.01IMVIMV$330K0.00N/AN/A($0.69) per share0.00ONCTOncternal Therapeutics$790K29.32N/AN/A$10.19 per share0.84OPTNOptiNose$70.99M1.47N/AN/A($0.77) per share-1.20PRQRProQR Therapeutics$7.05M23.20N/AN/A$0.55 per share3.65Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)IMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AONCTOncternal Therapeutics-$39.48M-$13.51N/AN/AN/A-5,029.17%-95.87%-83.56%5/2/2024 (Estimated)OPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)PRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)Latest OPTN, PRQR, EVFM, IMV, and ONCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 million3/7/2024Q4 2023ONCTOncternal Therapeutics-$3.09-$3.11-$0.02-$3.11$0.17 million$0.30 million 3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVFMEvofem BiosciencesN/AN/AN/AN/AN/AIMVIMVN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVFMEvofem BiosciencesN/A0.130.10IMVIMVN/A2.932.93ONCTOncternal TherapeuticsN/A6.946.94OPTNOptiNoseN/A0.600.55PRQRProQR Therapeutics0.103.543.54OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVFMEvofem Biosciences0.22%IMVIMV15.37%ONCTOncternal Therapeutics16.05%OPTNOptiNose85.60%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipEVFMEvofem Biosciences0.21%IMVIMV0.33%ONCTOncternal Therapeutics8.00%OPTNOptiNose2.20%PRQRProQR Therapeutics8.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableEVFMEvofem Biosciences3553.96 million53.85 millionNot OptionableIMVIMV9711.71 million11.67 millionOptionableONCTOncternal Therapeutics272.69 million2.47 millionOptionableOPTNOptiNose132112.65 million110.17 millionNot OptionablePRQRProQR Therapeutics15681.36 million74.52 millionOptionableOPTN, PRQR, EVFM, IMV, and ONCT HeadlinesSourceHeadlineProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual Meetingstockhouse.com - April 24 at 10:59 AMProQR defends RNA editing platform at EPOlifesciencesipreview.com - April 23 at 2:29 PMProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024globenewswire.com - April 23 at 7:00 AMComparing ProQR Therapeutics (NASDAQ:PRQR) & Teva Pharmaceutical Industries (NYSE:TEVA)americanbankingnews.com - April 23 at 1:44 AMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingfinance.yahoo.com - April 22 at 4:41 PMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingglobenewswire.com - April 22 at 4:31 PMProQR retains key patent for RNA editing technologyuk.investing.com - April 21 at 10:34 PMProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfoliostockhouse.com - April 20 at 8:50 PMCitigroup Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00americanbankingnews.com - April 20 at 4:50 AMProQR defends its Axiomer IP portfolio from new challengethepharmaletter.com - April 19 at 3:54 PMProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolioglobenewswire.com - April 19 at 7:00 AMProQR Therapeutics gets grant for oligonucleotide for reducing aberrant splice site selection in CEP290 genepharmaceutical-technology.com - April 18 at 1:28 PMCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00marketbeat.com - April 18 at 12:13 PMProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above Fifty Day Moving Average of $2.16americanbankingnews.com - April 16 at 3:56 AMProQR Therapeutics N.V. (PRQR)finance.yahoo.com - April 8 at 10:59 AMProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - March 29 at 2:14 AMBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disordersmarkets.businessinsider.com - March 14 at 7:10 PMBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platformmarkets.businessinsider.com - March 14 at 9:09 AMProQR Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 14 at 9:09 AMProQR Announces Year End 2023 Operating and Financial Resultsglobenewswire.com - March 13 at 7:00 AMProQR Therapeutics gets grant for nucleic acid molecule for converting uridine to pseudouridinepharmaceutical-technology.com - March 5 at 10:34 AMPRQR Mar 2024 2.500 callfinance.yahoo.com - February 18 at 1:10 PMProQR Therapeutics N.V.wsj.com - February 16 at 8:41 AMProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editingfinance.yahoo.com - February 15 at 8:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEvofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.IMVNASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Oncternal TherapeuticsNASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.